Jobs
-
United Therapeutics announced that its BREEZE study has demonstrated that patients with pulmonary arterial hypertension (PAH) who use Tyvaso treprostinil inhalation solution can safely switch to the Tyvaso treprostinil DPI. The company also announced that… Read more . . .
-
University of St Andrews spin out Pneumagen said that it has raised £2.5 million for clinical development of its Neumifil intranasal carbohydrate binding module (mCBM) for the prevention and treatment of respiratory viruses, including flu,… Read more . . .
-
Meissa Vaccines said that it has started dosing participants in its Phase 2 trial of MV-012-968 intranasal live attenuated vaccine candidate against respiratory syncytial virus (RSV). MV-012-968 is based on Meissa’s AttenuBlock platform, which it… Read more . . .
-
According to Impel NeuroPharma, the FDA has accepted the company’s 5O5(b)(2) NDA for its INP104 intranasal dihydroergotamine mesylate (DHE) for the treatment of migraine headaches and has set a PDUFA goal date of September 6,… Read more . . .
-
Synairgen said that the first patient has been dosed in the Phase 3 SG018 trial of its SNG001 inhaled interferon beta-1a in hospitalized COVID-19 patients, with the SG018 study expected to enroll 610 COVID-19 patients… Read more . . .
-
A new spin out from the University of California, Davis called InVixa announced that it has acquired the rights to UC Davis intellectual property related to delivery of statins to the lung for the treatment… Read more . . .
-
Canadian inhaler tracking and training start-up BreatheSuite has announced the completion of a $1.2 million financing round and said that it intends to use the funds for expanded distribution of its MDI add-on device in North… Read more . . .
-
Seelos Therapeutics announced that the first patients have been dosed in a Phase 2 study of its SLS-002 intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive… Read more . . .
-
Copley Scientific has announced the launch of an e-training service that allows customers to get live-streamed instruction in the use of OINDP testing equipment for in vitro testing. Both standard e-training packages and custom live-streamed… Read more . . .
-
Odyssey Group International said that it has signed a definitive agreement with Prevacus to acquire PRV-002, an intranasal therapy for the treatment of mild traumatic brain injury. As part of the deal, Prevacus CEO Jake… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK